Charles River Announces New and Continued Drug Discovery Collaborations
News Oct 09, 2015
Charles River Laboratories International, Inc. has announced new and continuing collaborations with three innovative drug discovery partners funded by the Wellcome Trust. Antabio, an anti-bacterial drug discovery company, Pcovery, a spin-out company focused on anti-fungals, and the British Columbia Cancer Agency have all extended existing or commenced new agreements with Charles River’s Global Discovery Services business.
“We are delighted Antabio, Pcovery, and the British Columbia Cancer Agency selected Charles River as their partner for the Wellcome Trust’s Seeding Drug Discovery (SDD) funded programs,” said Emily Hickey, Corporate Senior Vice President, Global Discovery Services, Charles River. “We look forward to supporting these organizations in their goal to identify new therapies to treat—and hopefully cure — diseases.”
As part of the agreements, Charles River’s Discovery Business will provide a comprehensive suite of in vitro and in vivo pharmacology, drug metabolism and pharmacokinetics (DMPK), and medicinal chemistry services, which are outlined below:
• For the British Columbia Cancer Agency, Charles River will begin a new project providing chemistry/computer-aided drug design (CADD), biochemical and cell assays, and in vitro and in vivo DMPK studies to improve radiotherapy treatments for cancer.
• For Antabio, Charles River will begin a new project developing a novel drug for infections in cystic fibrosis patients with project management, CADD, and medicinal and synthetic chemistry input. Charles River will also continue providing Antabio with medicinal and synthetic chemistry, CADD, and in vitro and in vivo DMPK services to develop drug candidates that inhibit antibiotic resistance.
• For Pcovery, Charles River will continue providing CADD and medicinal and synthetic chemistry support to develop antifungal treatments with the potential to destroy otherwise drug-resistant fungi.
For each project, the Charles River Discovery team worked closely with its respective partners, providing scientific support and insight into the development of the grant applications, and the generation and delivery of scientific presentations to the Wellcome Trust Scientific Advisory Board prior to project initiation.
Nano and Micro Join Forces to Treat OsteoarthritisNews
There is currently no treatment for curing osteoarthritis, which affects 80% of the population over 75 years of age. But researchers who have been studying the problem have come up with a new treatment that delivers previously-identified active principles directly into the joint in the form of nanocrystals inserted into microparticles.READ MORE
Fragile X: Drug Strategy Could Alleviate Behavioral & Cellular DeficienciesNews
Research in mice shows that a pharmacological strategy can alleviate multiple behavioral and cellular deficiencies in a mouse model of fragile X syndrome (FXS), the most common inherited form of intellectual disability and a major single-gene cause of autism spectrum disorders.READ MORE